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Abstract
Incidence rates vary 10-fold globally for colorectal cancer (CRC). Asia has lower rates than
Western countries, but as the Western life-style becomes more prevalent in economical‐
ly developing Asian countries, rates are increasing. Clinical therapy has improved over
the last few decades, and national screening programmes are a proven and effective means
of reducing mortality; chemoprevention through diet and life-style choices may provide
additional value. Diet has strong associations with the aetiology of CRC, considerable
epidemiological evidence exist that fruits and vegetables are associated with reduced risk
of CRC. There is also extensive experimental evidence that phytochemicals from fruit and
vegetables can modulate pathways of carcinogenesis. In this chapter, we consider Malaysia
specifically,  with  its  rich  ethnopharmacological  heritage  and  megabiodiversity;
Malaysian natural compounds may be a source of potentially chemo-protective with
relevance to CRC.
Keywords: colon cancer, in vitro, Malaysia, plants, anticancer
1. Introduction
Botanically, Malaysia is one of the most bio-diverse countries in the world with more than 23,000
plant species recorded [1]. Many components of these plants are traditionally used for flavour
and fragrances as well as for medicinal purposes. In line with bio-prospecting trend to find new
pharmaceutical lead compounds for medical applications; researchers from local academic and
research institutions within Malaysia have initiated investigations of the bioactive properties
of various native plants. In Malaysia, colorectal cancer is the second most frequent cancer after
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breast cancer [2]. The aim of this review is to collate data and conclusions from recent studies
undertaken on indigenous Malaysian plants with a view toward prevention and/or treatment
of colorectal cancer (CRC).
2. Epidemiology of CRC
The geographical distribution of CRC differs significantly (~10-fold) across the world with the
highest incidence rates in Australia/New Zealand (age-specific rate; ASR 44.8 and 32.2 per
100,000 in men and women, respectively), North America (ASR 30.1 and 22.7 per 100,000),
Europe (ASR 37.3 and 22.7 per 100,000), and Japan (ASR 42.1 and 23.5 per 100,000). The lowest
incidence rates occur in West Africa (ASR 4.5 and 3.8 per 100,000) although in this case, under-
reporting is likely due to incomplete coverage by registries [2].
The global rise of incidence and mortality rates attributable to cancer is likely due to the ageing
population, with incidence predicted to increase to 22.2 million cases globally by 2030 [3]. The
cancer pattern among countries exhibits a strong societal and economic influence, where
countries with a low human development index (HDI) (composite measure of life expectancy,
education, and gross domestic product per head) tend to have higher levels of infection-related
cancers (i.e., cervical) compared to medium and high HDI countries where the cancer burden
is more commonly related to reproductive, dietary, and hormonal factors (e.g., lung, breast,
and colorectal) [3]. As such, it is clear that CRC incidence rates increase in accordance with a
country’s income [4].
Asia as a whole consists mainly of developing countries and as such, incidence rates of CRC
(ASR 16.5 and 11.1 per 100,000 in men and women, respectively) are noticeably lower than for
the mainly developed countries of Europe—both in terms of incidence and in mortality (Table
1). However, cancer incidence and mortality in Asia is likely to rise over the next 20 years, due
in part to a rapid population expansion that will not be experienced by Western countries. This
increase will clearly impact on the health care burden associated with cancer, and also quality
of life across Asia as a whole. Ng and colleagues [4] recently considered the wide variation in
cancer incidence and mortality across Asia with respect to cancer survival, defining it in terms
of mortality to incidence ratios (MIR = 1 no effect on survival). Although cancer incidence is
lower in Asia, cancer survival is higher in Western countries as the MIRs are lower. Moreover,
while Eastern and Western Asia have a higher incidence of CRC compared to South-Eastern
and South-Central Asia, the pattern for survival is reversed in that the latter two regions have
poorer survival than Western and Eastern Asia [4]. In Malaysia (South Eastern Asia), CRC is
the second most common malignancy after breast cancer, while incidence rates exceed that of
China, cancer survival is similar. By contrast, in Japan, both incidence and survival are higher.
2.1. CRC pathogenesis
The majority of colorectal malignancies occur as sporadic forms that appear to arise from
benign adenomatous polyps, with carcinomas emerging slowly over a period of 10–20 years
[6–9]. Epidemiological data indicate that incidence and mortality rates of colorectal cancers
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(CRC) are greatly influenced by age rather than by gender. The majority of cases are detected
in individuals over the age of 60 [10], with 55% of cases occurring in more developed regions
in contrast to 52% of all CRC deaths which occur in the less-developed regions of the world,
reflecting poorer survival. For individuals diagnosed with CRC, it has been determined that
the 5-year survival rate is approximately 50–60% [11] and that survival among CRC patient is
improved if WCRF/AICR lifestyle guidelines on physical activity, body fatness, and diet are
adhered to [12]. The age-dependent increase in CRC development is associated with a multi-
step oncogenesis process and a number of histological stages, reflecting the accumulation of
genetic errors in somatic cells over time. Sporadic CRC is currently thought to arise via 1 of 3
identified molecular pathways (Micro Satellite instability—MSI, Chromosomal Instability—
CIN and CpG island methylator phenotype—CIMP) depending upon the individual’s
complement of gene alterations [13]. Conversely, the inheritance of germline mutations may
also result in development of neoplasms at an early age, with approximately 5% of CRC cases
being due to inherited single-gene syndromes such as familial adenomatous polyposis (FAP)
and hereditary non-polyposis colorectal cancer (HNPCC) [14]. It is estimated that as much as
12–35% of colon cancers can be explained by heritable factors, but known single-nucleotide
polymorphisms appear to explain only a small proportion of these [15].
The high degree of molecular heterogeneity present in CRC is reflected by the effectiveness of
chemotherapeutic regimes; however, the clinical significance of the majority of these individ‐
ual molecular alterations is still to be fully determined [16]. From a treatment perspective,
early-stage CRC is managed by surgical resection and advanced CRC with a combination of
chemotherapy and surgery. Most chemotherapeutic regimes use 5-Fluorouracil (5-FU) as the
main cytotoxic agent and this is commonly administered in conjunction with oxaliplatin for
adjuvant therapy for high-risk stage II/stage III CRC, and with either oxaliplatin or irinotecan
for metastatic CRC. Furthermore, the addition of bevacizumab-based chemotherapy (a
vascular endothelial growth factor (VEGF)-targeted agent) has proven to be more effective
than cytotoxic chemotherapy alone for the treatment of metastatic CRC [17].
While there is no doubt that CRC treatments have advanced over the last decade, improvement
in disease outcome has been more modest relative to the increase in treatment costs. Thus,
population screening is an important and cost-effective strategy given the improved prognosis
with early detection [18]. The pathogenesis of CRC makes it very well suited to population
screening especially given the correlation between disease stage and mortality. It is clear that
the detection and the removal of cancer precursors can reduce CRC incidence and mortality
and effective detection of CRC allows for less invasive treatment with a better prognosis. As
is to be expected, a large variation exists globally in the implementation of screening pro‐
grammes both in terms of strategy used (organised vs opportunistic) and standards applied
(diagnostic test, detection threshold), with implementation more common in Western coun‐
tries [19]. Europe for the most part has implemented an organized screening programme, while
the USA operates an opportunistic approach. In Asia, several countries have already devel‐
oped organized programmes including Japan, Korea and, to a lesser extent, China. As yet,
however, Malaysia has no organized screening in place. As cancer incidences are likely to
continue to rise, screening programmes will necessarily become more of an issue for low
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resource countries. Moreover, as cancer pattern types change, there will arise a need to
developed tailored approaches [19].
Region Incidence Mortality 5-year prevalence
Number ASR (W) Number ASR (W) Number Prop
Australian/New Zealand 18887 38.2 5489 10 54266 245.4
Europe 447136 29.5 214866 12.5 1203943 192.3
North America 158169 26.1 63465 9.4 486650 172.9
Asia 607182 13.7 331615 7.2 1493520 47
Asian region
Eastern Asia (EA) 421343 18.4 207716 8.4 1130066 87.1
Western Asia (WA) 27140 14.8 15306 8.4 62162 37.5
South Eastern Asia (SEA) 69016 12.5 43234 7.9 158845 35.7
South Central Asia (SCA) 89683 6.1 65359 4.4 142447 11.3
Country
Australia 15869 38.4 4168 9 45622 245.8
Japan (EA) 112675 32.2 49345 11.9 384877 350.8
UK 40755 30.2 16202 10.7 104047 200.5
Malaysia (SEA) 4539 18.3 2300 9.4 9714 47
China (EA) 253427 14.2 139416 7.4 583054 52.7
Saudi Arabia (WA) 2047 11.6 1094 6.6 4486 22.3
India (SCA) 64332 6.1 48603 4.6 86650 9.8
Incidence and mortality data for all ages. Five-year prevalence for adult population only. ASR (W) and proportions per
100,000 persons per year. The ASR is a weighted mean of the age-specific rates. Adapted from [5].
Table 1. Incidence and mortality rates (estimated, all sexes) for colorectal cancer, globally and within Asia and selected
regions.
2.2. Diet and CRC
The relatively recent increase in CRC incidence in Japan (Eastern Asia) and in urbanized
regions of China (Eastern Asia) is of significant concern [20] and is thought to be due to the
adoption of a more a Western lifestyle and diet [21]. Diet plays a central role in CRC patho‐
genesis, as those rich in saturated animal fat, and red meat (especially processed meat) [22]
together with alcohol intake [23] and smoking [24] have been positively associated with
colorectal neoplasia. Fruit and vegetable consumption is associated with a reduction in the risk
of CRC [25], and this concept is supported by a large body of case-control studies, although
results from cohort or prospective studies are less convincing [26]. Nevertheless, the protective
effects of fruits and vegetables against colorectal cancer are attributed to the large number of
Colorectal Cancer - From Pathogenesis to Treatment380
bioactive phytochemicals present within them [27], comprising mainly plant polyphenolic
secondary metabolites [28] and plant structural and storage polysaccharides which make up
dietary fiber [29, 30]. These various plant components or natural products are found within a
range of indigenous Malaysian fruit and vegetables, and thus may potentially play a role in
chemoprevention for CRC.
3. Natural product research in Malaysia
Natural products include a large and diverse group of substances produced by a variety of
sources including marine organisms, bacteria, yeasts, fungi, and plants [31]. Research on
natural products has focused primarily on the chemical properties, biosynthesis, and biological
functions of secondary metabolites [32]. Natural products, in particular plants, have been used
in traditional medicine and health practice. The World Health Organization has acknowledged
traditional medicine as a contributor to achieve health care objectives [33] and Malaysia,
blessed with its megabiodiversity and rich ethnopharmacological heritage, has been observed
to elegantly capitalize on these attributes with a view toward boosting the wealth and wellness
of its population [34].
In late 2010, the Malaysian government launched the Economic Transformation Programme
(ETP), which focuses on 12 National Key Economic Areas (NKEAs). The Agriculture sector,
under the purview of the Ministry of Agriculture (MoA) is one of the NKEA-identified areas
where the Entry Point Project 1 (EPP1) is focused on high-value herbal products. The MoA has
overseen the establishment of five R&D clusters, which focus on, respectively, discovery, crop
production, and agronomy, standardization and product development, toxicology/pre-clinical
and clinical studies, and processing technology. The initial phase of this EPP was focused on
ensuring the supply of five main local herbs, namely Tongkat Ali (Eurycoma longifolia Jack),
Misai Kucing (Orthosiphon aristatus (Blume) Miq.), Hempedu Bumi (Andrographis paniculata
(Burm.f.) Nees), Dukung Anak (Phyllanthus niruri L.) and Kacip Fatimah (Marantodes pumi‐
lum (Blume) Kuntze (syn. Labisia pumila (Blume) Mez). Subsequently, six more herb species
were added to the project, including Mengkudu (Morinda citrifolia L.), Roselle (Hibiscus
sabdariffa L.), Ginger (Zingiber officinale), Mas Cotek (Ficus deltoidea Jack), Belalai Gajah
(Clinacanthus nutans (Burm.f.) Lindau) and Pegaga (Centella asiatica (L.) Urb) [35]. In 2014, eight
products developed through the EPP 1 underwent pre-clinical trials. It is estimated that
commercialization of the identified herbs will contribute MYR2.2 billion to the Gross National
Income (GNI) by 2020 [35].
In Malaysia, research on natural products including the EPP-listed local herbs described above
is being undertaken by research centers and institutions of higher learning (Table 2). Never‐
theless, research in this area is also being carried out by various independent research groups
in the local academia.
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Entities Institutions
Advanced Medical and Dental Institute Universiti Sains Malaysia (USM)
Atta-ur-Rahman Institute for Natural Product Discovery Universiti Teknologi MARA (UiTM)
Bioresource and Drug Discovery Research Group (BDD), Faculty
Science and Natural Resources (FSSA)
Universiti Malaysia Sabah (UMS)
Centre For Natural Products And Drug Research (CENAR) Universiti Malaya (UM)
Drug Discovery and Development Research Group (under purview
of the Natural Products Cluster)
Universiti Kebangsaan Malaysia (UKM)
Institute of Bioproduct Development (IBD) Universiti Teknologi Malaysia
Laboratory of Natural products, Institute of Bioscience Universiti Putra Malaysia (UPM)
Natural Medicine Products Centre (NMPC) International Islamic University Malaysia (IIUM)
Natural Product and Drug Discovery Centre (NPDC) Malaysian Institute of Pharmaceuticals and
Nutraceuticals (IPharm)
Natural Product Lab, Institute of Marine Biotechnology Universiti Malaysia Terengganu (UMT)
Natural Products Division Forest Research Institute Malaysia (FRIM)
Table 2. Entities involved in natural product research and development in Malaysia.
4. Studies of the effect of Malaysian plants on colon cancer
It has been estimated that around 1200 medicinal plants have potential pharmaceutical value
[1]. Many of these species have been scientifically investigated by researchers seeking to
provide evidence of effectiveness toward different diseases such as cancer, diabetes, arthritis,
heart diseases, and many others. However, work on the effects of Malaysian plants on colon
cancer specifically has been very limited (Tables 3 and 4). Nonetheless, several observations
may be made on work undertaken to date that allow trends to be identified for the future of
such work.
It is clear that there is no focused approach on any particular species, and most of the studies
were conducted at the early stage of screening for anti-cancer effects with little in the way of
continued development thereafter. This work includes cytotoxicity screening of crude extracts
or compounds derived from solvent fractions against several types of cancer using in vitro cell
line-based experiments. While the species investigated are edible herbs and fruit plants, in
several instances, the parts of the plant investigated may not be commonly consumed as food.
For instance, Moghadamtousi et al. [36] studied the leaf of soursop plant, rather than the more
commonly consumed fruits, while Aisha et al. [38] investigated the rind of mangosteen fruit
instead of the flesh. To this end, selection of species seems to be based on ethnomedicinal
evidence within local communities and capitalizing upon the novelty aspect in that the species
(or parts of plants) have not been investigated by other groups. The use of inedible plant parts
may be also be related to the zero waste and health to wealth concepts where all parts of plants
Colorectal Cancer - From Pathogenesis to Treatment382
are considered potential biomass to be exploited. As such, materials from inedible parts of
plants may be more cost-effective to be used. Furthermore, the majority of studies appear to
be “isolated studies” with lack of continuing development as stated above, which may perhaps
be due to lack of funding and proper planning for future work including networking. The lack
of funding may also correspond to lack of facilities and equipment required to do further in
depth robust work.
Plant and
part of plant
used 
Common
name 
Compound/
extract
tested
Type of study  Details/IC50 Reference
Annona
muricata L.
(Leaf)
Graviola,
soursop;
adurian
belanda
Ethyl acetate
extract
In vitro HCT 116,
HT29
and CCD841 cell
lines
In vitro cytotoxicity
IC50 = 4.29 ± 0.24 μg/ml (HT29)
IC50 = 3.91 ± 0.35 μg/ml (HCT116)
IC50 = 34.24 ± 2.12 μg/ml (CCD841)
[36]
5-Fluorouracil (positive control)
IC50 = 1.10 ± 0.11 μg/ml (HT29)
IC50 = 0.90 ± 0.09 μg/ml (HCT116)
The extract also showed cell cycle
arrest at G1, induction
of apoptosis, anti-migration
and anti-invasive effects.
Annona
muricata L.
(Leaf)
Graviola,
soursop;
adurian
belanda
Ethyl acetate
extract
In vitro HT29
and CCD 841
cell lines.
In vitro cytotoxicity
HT29
IC50 = 5.72 ± 0.41 μg/ml (12 h)
IC50 = 3.49 ± 0.22 μg/ml (24 h)
IC50 = 1.62 ± 0.24 μg/ml (48 h)
[37]
CCD 841
IC50 = 64.32 ± 3.76 μg/ml (12 h)
IC50 = 47.10 ± 0.47 μg/ml (24 h)
IC50 =32.51 ± 1.18 μg/ml (48 h)
In vivo AOM-
induced colon
cancer in rats
Aberrant Crypt
formation after 2 weekly
injections of extract.
250 mg/kg = 61.2% inhibition
500 mg/kg = 72.5% inhibition
5-FU = 79.5% inhibition
Garcinia
mangostana
(Fruit rind)
Mangosteen;
amanggis
Xanthone (81%
α-mangostin
and 16% γ-
In vitro
HCT 116 cell line
In vivo
Subcutaneous
tumor of
In vitro cytotoxicity
 1) IC50 = 6.5 ± 1.0 μg/ml
 2) IC50 = 5.1 ± 0.2 μg/ml
 3) IC50 = 7.2 ± 0.4 μg/ml
IC50 of Cisplatin (positive
[38]
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Plant and
part of plant
used 
Common
name 
Compound/
extract
tested
Type of study  Details/IC50 Reference
mangostin) from
toluene extract
of the fruit
α-mangostin
γ-mangostin)
HCT116 on nude
mice
control) = 6.1 ± 0.2 μg/ml
The extract also showed
induction of apoptosis, anti-
tumorigenicity and up-
regulation of MAPK/ERK, c-Myc/Max,
and p53 cell signalling pathways
In vivo Xanthones extract caused
significant
growth inhibition of
the subcutaneous tumor
Garcinia
mangostana
(Fruit rind)
Mangosteen;
amanggis
Hexane and
ethyl acetate
(Other extracts
produced,
butanol and
methanol)
In vitro
Caco-2 cell line
(also tested on other
cells KB and PBMC)
In vitro cytotoxicity
IC50 = 13.0 ± 3.8 μg/ml
(Hexane) IC50 = 8.1 ± 0.1 μg/ml
(Ethyl acetate) IC50 of
Tamoxifen positive
control = 4.0 ± 0.4 μg/ml
[39]
Garcinia
mangostana
(Fruit rind)
Mangosteen;
amanggis
α-mangostin
β-mangostin
γ-mangostin
hexane extracts
In vitro
DLD-1 cells
All three extracts showed
anti-proliferative effects
at 20 μM.
[40]
Table 3. Studies of anticancer effects of plant materials obtained from fruit trees in Malaysia.
Plant and part
of
plant used 
Common
name 
Compound/extract
tested
Type of
study 
Details/IC50 References
Alpinia mutica
(Rhizome)
aTepus Methanol and
fractionated
extracts 
(hexane, ethyl
acetate and
water)
In vitro
HT 29 and
HCT 116
cell line
(also tested on
other cell lines;
KB, CasKi,
MCF-7, A549
and MRC-5)
Hexane extracts showed IC50 of
36.1 ± 1.1 μg/ml (HCT116)
and 47.4 ± 1.6 μg/ml (HT29)
Ethyl acetate extracts showed
IC50 of 20.4 ± 3.2 μg/ml
(HCT116) and 24.2 ± 0.04 μg/ml
(HT29) Methanol and water
extracts showed IC50 of
more than 100 μg/ml
IC50 of
doxorubicin (positive
control) = 0.24 ± 0.04 μg/ml
(HCT116) and 0.33 ± 0.03 μg/ml
[41]
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Plant and part
of
plant used 
Common
name 
Compound/extract
tested
Type of
study 
Details/IC50 References
(HT29)
Casearia
capitellata
(Leaf)
Baccaurea
motleyana
(fruits and
peel)
Phyllanthus
pulcher (Leaf,
stem and root)
Strobilanthus
crispus (Leaf,
flower)
aSimmilit
matangi
aRambai
aNaga
buana
aPecah
kaca/Pecah
beling/
Pokok
pecah/Jin
batu/
Hexane,
dichloromethane,
ethyl acetate and
methanol extracts,
respectively
In vitro
HT29 cell line
(also tested on
other cell lines;
MCF-7, DU-
145 and H460)
DCM extract of P.pulcher
root showed the lowest IC50
among the extracts tested against
HT29 cells (IC50 = 8.1
± 0.5 μg/ml)
[42]
Curcuma
mangga
(Rhizome)
aTemu
pauh/
Kunyit
mangga
Crude methanol
and fractionated
extracts (hexane,
ethyl acetate)
In vitro
HT 29 and
HCT 116 cell
line(also
tested on
other cell
lines; KB,
CasKi,
MCF-7, A549
and MRC-5)
Extracts showed the IC50 between
29.4 ± 0.2 and 36.8 ± 3.8 μg/ml
against HCT116 cells
Extracts showed
the IC50 between 17.9 ± 0.3
and 22.0 ± 1.1 μg/ml against
HT29 cells
IC50 of doxorubicin
(positive control) = 0.24
± 0.04 μg/ml (HCT116)
and 0.33 ± 0.03 μg/ml
(HT29) Isolated compounds
from the extracts also
showed high cytotoxicity
effects towards both
cell lines
(between 6.3 ± 0.26 and 14.9
± 0.40 μg/ml) Several isolated
compounds from the extracts
also showed considerable
cytotoxicity effects against
the cancer cells
[43]
Curcuma
mangga
(Rhizome)
aTemu
pauh/
Hexane and
ethyl acetate
extracts.
In vitro
HT29 and
CCD-18Co
In vitro cytotoxicity (72 h)
Hexane:
IC50 = 17.9 ± 1.2 μg/ml (HT29)
[44]
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Plant and part
of
plant used 
Common
name 
Compound/extract
tested
Type of
study 
Details/IC50 References
Kunyit
mangga
IC50 = 45.7 ± 1.0 μg/ml (CCD-18Co)
Ethyl acetate:
IC50 = 15.6 ± 0.8 μg/ml (HT29)
IC50 = 46.5 ± 0.1 μg/ml (CCD-18Co)
Pereskia bleo
(Kunth) DC.
(Cactaceae)
(Leaf)
aJarum
tujuh bilah
Compounds from
ethyl acetate
fraction
• Dihydroactini
diolide
• β-sitosterol
• 2,4-di tert butyl
phenol
• α-tocopherol
• Phytol
In vitro
HCT 116 cell
line
(also tested on
other cell lines;
KB, CasKi,
MCF-7, A549
and MRC-5)
Dihydroactinidiolide showed the
lowest IC50 at 5 μg/ml against
HCT116 cells Dihydroactinidiolide
showed IC50 of 91.3 μg/ml
against MRC-5 cells
IC50 of doxorubicin (positive
control) = 0.36 μg/ml
(HCT116) and 0.55 μg/ml (MRC-5)
[45]
Piper betle
(Leaf)
aSirih Aqueous extract In vitro
HCT 116 and
HT29 cell lines
In the presence of the extract,
a lower dosage of 5-FU is required
to achieve the maximum drug
effect in inhibiting the
growth of HT29 cells. However,
the extract did not significantly
reduce 5-FU dosage in HCT116
cells
[46]
Strobilanthus
crispus (part of
plant used not
stated )
aPecah
kaca/Pecah
beling/
Pokok
pecah/Jin
batu/
Crude ethanol
extract and
fractions obtained
from column
chromatography
In vivo
Sprague
Dawley (SD)
male rats
In vitro
HT29, CCD841
S. crispus ethanol extract
protects against CRC formation
(azoxymethane-
induced aberrant crypt foci) in
rats Exposure of HT29 and CCD-841
to extract and several fractions
(tested between 0 and 500 μg/ml)
induced a concentration dependent
decrease in cell viability
[47]
Zingiber
officinale
(rhizome)
Ginger;
ahalia
Ginger: Water-
based ultrasonic
assisted extraction
Honey: Packaged
in plastic
containers and
In vitro
HT29 cell lines
In vitro cytotoxicity
IC50 = 5.2 mg/ml (ginger alone)
IC50 = 80 mg/ml (Gelam honey
alone) The combinations of 3 and
4 mg/ml of
ginger with 27 and 10 mg/ml
[48]
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Plant and part
of
plant used 
Common
name 
Compound/extract
tested
Type of
study 
Details/IC50 References
sterilized using
gamma radiation
of Gelam honey showed combination
index (CI) values of 0.92 and 0.90,
respectively, indicating
synergistic effects.
Cell death in response
to the combined ginger and
Gelam honey treatment was
associated with the
stimulation of early
apoptosis
Zingiber
officinale
(rhizome)
Ginger;
ahalia
Ethanol extract In vitro
HCT 116 and
HT29 cell lines
Inhibition of proliferation
IC50 (HCT116) = 496 ± 34.2
μg/ml IC50 (HT29) = 455 ±
18.6 μg/ml Induction of
apoptosis at 500 μg/ml
extract 35.05% (HCT116) and
19.81% (HT29) Ginger extract
arrested HCT 116 and HT 29
cells at G0/G1 and G2/M
phases with corresponding
decreased in S-phase
[49]
aLocal name in Malay language.
Cell lines: A549 (and human lung carcinoma cell line); CasKi (human cervical carcinoma cell line); CCD841 (normal
human colon epithelial cell line); DU-145 (prostate cancer cell line); H460 (lung cancer cell line); HCT116 (colon cancer
cell line); HT29 (colon cancer cell line); KB (human nasopharyngeal epidermoid carcinoma cell line); MCF-7 (hormone-
dependent breast carcinoma cell line; MRC-5 (non-cancer human fibroblast cell line).
Table 4. Studies of anticancer effects of plant materials obtained herbs and spices in Malaysia.
Some species investigated for their effects against colon cancer in the listed studies have also
been investigated for other biological effects. For example, prior to the report by Abdul Malek
et al. [43], Alpinia mutica was previously reported to have inhibitory activity towards lipid
oxidation [50] and anti-bacterial effects against Bacillus subtilis and methicillin-resistant
Staphylococcus aureus (MRSA) [50] in addition to anti-platelet aggregation activities [51].
For in vitro work, two types of commercially available colon cancer cell lines, HT29 and
HCT116, were used in the majority of studies. However, there is no consistency in the positive
controls used in the empirical studies. Some studies include work on CCD841 normal human
colon epithelial cells [36, 47], while others include work on 5-Fluorouracil [46, 47], doxorubicin
[45], or cisplatin [38] as positive control. Cytotoxic screening results from the studies listed in
Table 3 and Table 4 showed that effects on colon cancer were only moderate as compared to
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other cells lines tested. The follow-up study by Moghadamtousi et al. [37] demonstrated
significant decreases in aberrant crypt foci counts in an AOM-induced CRC animal model
supporting prior observation in vitro. The limited success of in vitro studies excluding the
aforementioned study may explain the lack of in-depth studies on the effects of the extracts
on colon cancer following the screening phase.
The colon cancer cell lines used in the studies differ in their origin, mutation status and
metabolic requirements [52]. For example, HT29 cells utilize glucose through the pentose
phosphate pathway [53], whereas HCT116 cells have higher requirements for glutamine [52,
54]. In terms of gene expression, HT29 is deficient in expression of p53 [55], while HCT116 cells
possess mutations in PI3KCA and KRAS genes which confer constitutive activation of
PI3K/AKT and KRAS pathways [56]. Since the two cells lines have different characteristics, the
use of such cell lines in preliminary studies is substantial as it can set forth the mechanistic
investigations on the effects of the plants against colon cancer.
Although the majority of work was in vitro-based preliminary work, Al-Henhena et al. [47]
reported both in vitro and in vivo studies on Strobilanthus crispus. Meanwhile, some studies
investigated the cytotoxic effects of not only the crude extracts and fractions, but also tested
the isolated compounds [38, 40, 45]. Among the studies reported, the same group showed a
more thorough investigation of the species selected. Other researchers have combined the
selected species with other components to determine their combined effects on colon cancer
cells. For instance, Ng et al. [46] looked at the potential effects of Piper betle leaf extract to reduce
the 5-Fluorouracil dosage required to exert the same cytotoxicity in HT29 and HCT116 cells.
Tahir et al. [48] studied the combined effects of Zingiber officinale extracts and Gelam honey on
viability of HT29 cells. Some researchers have also studied the potential mechanism of the
selected species beyond cytotoxicity tests. Garcinia mangostana rind extracts showed induction
of apoptosis, anti-tumorigenicity, and upregulation of MAPK/ERK, c-Myc/Max, and p53 cell
signaling pathways [38] while Annona muricata leaf extracts showed cell cycle arrest at G1,
induction of apoptosis, anti-migration, and anti-invasive effects [36]. While the follow-up
study by Moghadamtousi et al. [37] supports the previous in vitro observations with aberrant
crypt foci counts significantly reduced by the treatment in an AOM induced CRC animal
model. Taken together, studies on Malaysian plants against colon cancer are at different
technological levels with, consequently, very limited data to enable a consensus to be made.
Compounding the lack of consensus and technical variability is the fact that choice of journals
in which to publish is still very much dependent on funding; thus, publishing in the open
access journals with high impact factors can only be afforded by certain groups of researchers.
This clearly will have hampered the dissemination of research data as, while it may be
beneficial for researchers to reach a wider audience at the early stage of work, this may
correspond to having to publish in a low-cost, lower impact journals due to lack of funding.
From another perspective, higher impact journals often require more conclusive data, which
in turn means more experimental work—early stage work may not meet such journals’
publication criteria and may be perceived to be low quality. Therefore, it would be more
favorable to have a mechanism to help improve the dissemination of work in order to enhance
the overall research and development in the subject area.
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Based on the publications considered in Tables 3 and 4, it was also observed that authors did
not always report the local names of species investigated. Since these are local plants that may
not even have English names, it is to be recommended that this information is included
together with full description of the species investigated. This could be one way to present the
potential positive effects of the species to a wider scientific community thereby increasing the
impact and scientific value of the work. Thus, the correct taxonomy including genus, species
and family should be given for accuracy.
5. Conclusion
Some Malaysian plants that show anti-cancer effects towards colon cancer include Alpinia
mutica (tepus), Annona muricata (soursop), Baccaurea motleyana (rambai), Casearia capitellata
(simmilit mantangi), Curcuma manga (temu pauh), Garcinia mangostana (mangosteen), Pereskia
bleo (Kunth) (jarum tujuh bilah), Phyllanthus pulcher (naga buana), Strobilanthus crispus (pecah
kaca), and Zingiber officinale (ginger).
Nevertheless, much of the scientific evidence is preliminary at best despite the selection of
plant species for study based upon ethnomedicinal practices. The introduction of the EPP by
the Malaysian government is a commendable effort to raise the value of indigenous Malaysian
plants in the pharmaceutical sector. However, a more concerted approach to the work is
necessary including a comprehensive review of the existing data in order to fully exploit local
plants toward prevention and treatment of colon cancer.
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